Modality
Nanobody
MOA
USP1i
Target
ALK
Pathway
STING
SLEParkinson's
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
May 2018
→ Jun 2031
Phase 2Current
NCT06179741
2,259 pts·Parkinson's
2018-05→2031-06·Not yet recruiting
2,259 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-055.2y awayPh2 Data· Parkinson's
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Not yet…
Catalysts
Ph2 Data
2031-06-05 · 5.2y away
Parkinson's
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06179741 | Phase 2 | Parkinson's | Not yet recr... | 2259 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Niralucimab | Ionis | Phase 1 | ALK |